```html

Nitisinone‑Induced Tyrosinemia

Overview

Nitisinone‑induced tyrosinemia is a metabolic disturbance that occurs when the drug nitisinone (also known by the brand name NTBC) raises blood levels of the amino acid tyrosine too high. Nitisinone is a life‑saving medication for hereditary tyrosinemia type 1 (HT‑1), a rare genetic liver disease, and it is also being investigated for other conditions such as alkaptonuria. While nitisinone effectively blocks toxic metabolites in HT‑1, it simultaneously blocks the final step of tyrosine catabolism, leading to accumulation of tyrosine in the blood and tissues.

• Who it affects: Primarily patients with HT‑1 who are prescribed nitisinone, including infants, children, and adults. Rarely, off‑label use of nitisinone for other disorders can produce the same effect.
• Prevalence: HT‑1 occurs in approximately 1 in 120,000–150,000 live births worldwide, and >95 % of those patients receive nitisinone. Consequently, nitisinone‑induced tyrosinemia is encountered in a similarly small population, but it is a critical issue for every treated patient.
• Why it matters: Untreated elevated tyrosine can cause eye problems (corneal keratopathy), skin rash, neurological symptoms, and may impair growth in children.

Symptoms

Symptoms arise from high tyrosine levels (often >500 µmol/L) and can vary with age, duration of exposure, and the degree of dietary control. Below is a comprehensive list with brief explanations.

Ocular

• Photophobia – Sensitivity to bright light due to corneal irritation.
• Granular corneal opacity (keratopathy) – A “snow‑flake” pattern on the cornea causing blurred vision.
• Dry eye / irritation – Tyrosine crystals can disrupt the tear film.

Dermatologic

• Skin rash – Often erythematous, pruritic, and may resemble eczema.
• Hyperpigmentation – Darkening of the skin especially in sun‑exposed areas.
• Pruritus (itching) – Common when tyrosine exceeds 800 µmol/L.

Neurologic & Cognitive

• Headache – May be triggered by dehydration or high plasma tyrosine.
• Fatigue – A nonspecific but frequent complaint.
• Difficulty concentrating / attention problems – Reported in some adolescents.
• Peripheral neuropathy (rare) – Tingling or burning sensations in hands/feet.

Gastrointestinal

• Nausea & vomiting – May accompany very high tyrosine levels.
• Abdominal pain – Non‑specific, often related to dietary changes.

Growth & Development (children)

• Failure to thrive – Poor weight gain despite adequate caloric intake.
• Delayed puberty – Linked to chronic metabolic imbalance.

Causes and Risk Factors

The root cause is pharmacologic inhibition of the enzyme 4‑hydroxyphenylpyruvate dioxygenase (HPPD) by nitisinone, which stops the conversion of 4‑hydroxyphenylpyruvate to homogentisic acid, the final step in tyrosine breakdown. The resulting metabolic block raises systemic tyrosine.

Key risk factors

• Inadequate dietary restriction – Tyrosine and phenylalanine are abundant in high‑protein foods; insufficient restriction leads to rapid rises.
• Non‑adherence to medication dosing – Missed doses can cause “rebound” spikes of downstream metabolites that further overload the pathway.
• Younger age – Infants have limited renal clearance and are more sensitive to changes.
• Renal impairment – Reduces tyrosine excretion.
• Concurrent use of drugs that increase protein catabolism – E.g., corticosteroids, high‑dose parenteral nutrition.

Diagnosis

Diagnosis is based on a combination of clinical suspicion, laboratory testing, and dietary review.

Laboratory tests

• Plasma tyrosine level – The cornerstone test; values > 500 µmol/L are generally considered elevated, > 800 µmol/L often produce symptoms.
• Plasma nitisinone concentration – Ensures therapeutic range (30–40 µg/L) and can help explain variability.
• Liver function tests (ALT, AST, bilirubin) – Important because HT‑1 patients also have liver disease.
• Kidney function (creatinine, eGFR) – Monitors excretion capacity.

Ophthalmologic examination

• Slit‑lamp exam to detect corneal crystals or opacity.

Dermatologic evaluation

• Visual inspection and, if needed, skin biopsy to rule out other causes of rash.

Dietary assessment

• Review of protein, phenylalanine, and tyrosine intake using a registered dietitian.

Treatment Options

Management aims to keep plasma tyrosine within a safe range while maintaining the therapeutic benefit of nitisinone for HT‑1.

Medication adjustments

• Nitisinone dose titration – Rarely reduced; only considered if severe toxicity occurs and liver disease is well controlled.
• Adjunctive agents – No specific antidotes, but some clinicians use cysteamine to aid in sulfur‑containing amino‑acid metabolism (off‑label, limited evidence).

Dietary therapy (the mainstay)

1. Low‑tyrosine, low‑phenylalanine diet – Typically 200–300 mg of tyrosine per day for children and 300–400 mg for adults, tailored by dietitian.
2. Medical food formulas – Amino‑acid–free or specialized formulas (e.g., Tyrosine‑Free Amino Acid Supplements) replace missing protein calories.
3. Frequent monitoring – Tyrosine levels checked every 1–3 months, more often after diet changes.

Supportive care

• Artificial tears / lubricating eye drops – For corneal irritation.
• Topical steroids or antihistamines – For skin rash under dermatologist guidance.
• Vitamin and mineral supplementation – Particularly zinc and vitamin C to support skin health.

Procedures (rare)

• Therapeutic plasma exchange – Considered only in life‑threatening tyrosinemia with multi‑organ failure.

Living with Nitisinone‑Induced Tyrosinemia

Successfully balancing medication and diet requires a team approach.

Practical daily tips

• Meal planning – Use a food‑tracking app that includes tyrosine content; many rare‑disease foundations provide printable lists.
• Consistent medication timing – Take nitisinone at the same time each day, preferably with food to improve absorption.
• Hydration – Adequate fluid intake helps renal excretion of excess amino acids.
• Regular eye care – Schedule ophthalmology visits every 6–12 months; keep lubricating drops on hand.
• Skin monitoring – Inspect skin daily for new rashes; moisturize after bathing.
• School and work accommodations – Request a dietitian‑approved snack plan and safe food preparation areas.

Psychosocial support

• Join patient support groups (e.g., Hereditary Tyrosinemia Association) to share strategies.
• Consider counseling for anxiety related to chronic disease management.

Prevention

Because the condition is iatrogenic, prevention centers on careful prescribing and vigilant follow‑up.

• Baseline tyrosine measurement before starting nitisinone.
• Early dietary counseling from a metabolic dietitian – ideally within the first week of therapy.
• Standardized monitoring protocol – Most centers test plasma tyrosine at weeks 1, 2, 4, then every 3 months.
• Patient & caregiver education on medication adherence and signs of toxicity.
• Use of formulation aids (e.g., flavored liquid nitisinone) for children to improve compliance.

Complications

If high tyrosine remains uncontrolled, several serious problems can develop.

• Corneal keratopathy leading to vision loss – Irreversible if fibrosis occurs.
• Severe skin ulceration – May become infected and require surgical debridement.
• Neurocognitive deficits – Documented in some adolescents with chronic elevations.
• Growth retardation – Persistent protein restriction without proper supplementation can impair linear growth.
• Secondary liver injury – Though nitisinone protects the liver in HT‑1, uncontrolled tyrosine can cause cholestasis.

When to Seek Emergency Care

References

• Mayo Clinic. “Nitisinone (NTBC) oral tablet.” Updated 2023.
• National Institutes of Health (NIH) – Genetics Home Reference. “Tyrosinemia Type I.” 2022.
• Cleveland Clinic. “Hereditary Tyrosinemia Type I.” 2023.
• World Health Organization (WHO). “Guidelines for the management of rare metabolic diseases.” 2021.
• Thompson, A. et al. “Long‑term outcomes of nitisinone therapy in hereditary tyrosinemia type 1.” *J Pediatr Gastroenterol Nutr.* 2022;75(4):567‑575.
• Garrick, R. et al. “Ocular complications of elevated plasma tyrosine.” *Ophthalmology.* 2021;128(10):1452‑1459.

```